A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/ Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Is this Study for You?

Let's Get Started!




Cherry Creek Medical Center
University of Colorado Hospital

Principal Investigator
Photograph of Virginia Borges

Virginia Borges

Study ID

Protocol Number: 21-3077

More information available at ClinicalTrials.gov: NCT04862663

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers